Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published September 8, 2014.
Author Disclosures
- Paul Browne, PhD,
- Dhia Chandraratna, PhD,
- Ceri Angood, MPH,
- Helen Tremlett, PhD,
- Chris Baker, MPH,
- Bruce V. Taylor, MD and
- Alan J. Thompson, MD, FRCP
- Paul Browne, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen Idec, (2)Genzyme, (3) Novartis, (4) Merck Serono, (5) Synthon, (6) Teva
NONE
NONE
(1) Vanneau Trust
NONE
NONE
NONE
NONE
NONE
NONE
- Dhia Chandraratna, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis International Federation, Head of Research
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ceri Angood, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Helen Tremlett, PhD,
NONE
NONE
Dr Helen Tremlett is funded by the Multiple Sclerosis Society of Canada (Don Paty Career Development Award), Michael Smith Foundation for Health Research and is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. She has received: research support from the US National Multiple Sclerosis Society, CIHR, and UK MS Trust; speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres, US National MS Society, the University of British Columbia Multiple Sclerosis Research Program, Bayer Pharmaceutical (speaker, 2010, honoraria declined), Teva Pharmaceuticals (speaker 2011), ECTRIMS (2011, 2012, 2013), UK MS Trust (2011), the Chesapeake Health Education Program, US Veterans Affairs (2012, honorarium declined), Novartis (2012) and the Consortium of MS Centers (2013). Unless otherwise stated, all speaker honoraria are either donated to an MS charity or to an unrestricted grant for use by her research group.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Canadian Institutes of Health Research [#190898 (PI) and #MOP-82738 (PI)]; the US National Multiple Sclerosis Society (Operating grants: 2006-09 and 2009-12), the Multiple Sclerosis Society of Canada (Don Paty Career Development Award, 2004-present), and a Michael Smith Foundation for Health Research Scholar Award (2006- present); Canada Research Chair in Neuroepidemiology and Multiple Sclerosis
NONE
NONE
NONE
NONE
NONE
NONE
- Chris Baker, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
(1) London School of Hygiene and Tropical Medicine, Research Fellow, 0.3 years
(1) Multiple Sclerosis International Federation (2) Department of Chemistry, University of Washington
NONE
NONE
NONE
NONE
NONE
(1) University of Washington, Seattle, Washington, USA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bruce V. Taylor, MD and
Biogen Idec Tecfidera advisory board Australia
NONE
Funding to travel to World Congress of MS Montreal September 2008 from Bayer Schering Pharma Pty Ltd Funding for travel and accommodation from MS Society of Western Australia to speak at their 2008 scientific. meeting. Funding from Bayer Schering Pharma to present a series of lectures in South East Asia March 2008 Invited Guest speaker at Asia pacific MS forum funded by Bayer Schering Pharma Pty Ltd Invited guest speaker INDAPS meeting Melbourne Nov 2008 funded by CSL Pty Ltd Austrlaia. Funding to travel to AAN meeting Seattle 2009 from Bayer Schering Pharma. Funding to travel to ECTRIMS Gothenberg 2010 from Bayer Schering Pharma. Funding to travel to ECTRIMS meeting Lyon France 2012 fromBayer Schering. Funding to travel to AAN San Diego 2013from Novartis. Funding to Travel to ECTRIMS 2013 from Novartis
International MS Journal Editorial Advisary Board 2009 - 2012 Journla of Neurology Neurosrugery and Psychiatry Editorial Board From Jan 2013
NONE
NONE
Honoraria received from MS society of Western Australia for speaking at the 2008 Scientific meeting
NONE
NONE
NONE
NONE
NONE
NHMRC australia project grant support.2008-9.490020, 2009 544922 2010 2012 1047180 HRC New Zealand project grant support.2007-8 05/524 National MS Society of USA project grant support Australian research Council and MS Research Australia 2007-9 LP0776744 National MS society of US project grant funding
NONE
Ms society of Tasmania research fellowship support 2007 - 2009
NONE
NONE
NONE
NONE
NONE
NONE
- Alan J. Thompson, MD, FRCP
(1) Eisai Ltd, Chair of the Advisory Committee (Clinical Neuroscience)2010-March 2013, honorarium to UCL; (2) Chair of the Eisai-UCL Joint Steering Committee for Neuroscience April 2013 to date, honorarium to UCL (3) Imanova, Board member,2012-2014,no compensation; (4) Genzyme, member European Advisory Board (Teriflunomide, Alemtuzumab), June 2013, honorarium and support for travel; (5) Biogen Idec, 14 March 2014, honorarium and support for travel; (6) medDay, 6 May 2014, honorarium and support for travel.
NONE
(1) Serono Symposia International Foundation (EXCEMED), Invited lectures,honoraria and support for travel; 2) Novartis, Invited lecturer, honorarium and support for travel; (3) Teva, Invited lecturer, honorarium; (4) Remedica, invited lecturer, honorarium and support for travel.
(1) Multiple Sclerosis Journal,Editor-in-Chief, 2006 to date,honorarium (2) Lancet Neurology,Editorial Advisory Board, 2007 to date, free subscription
NONE
Multiple Sclerosis, Cambridge University Press, 2011
NONE
NONE
NONE
(1) Development Foundation, Brain Appeal, National Hospital for Neurology and Neurosurgery, Queen Square, London, trustee, no remuneration. (2) National Institute for Health Research, Senior Investigator, honorarium. (3) Multiple Sclerosis International Federation (MSIF), Board member and Chair of the International Medical and Scientific Board, no remuneration, support for travel. (4) International Progressive MS Alliance, chair Scientific Advisory Committee, no remuneration, support for travel. (5) National Multiple Sclerosis Society, member, Research Programs Advisory Committee,member, no remuneration, support for travel. (6) The Worshipful Company of Pewterers, trustee, no remuneration.
NONE
(1) Eisai Inc. to support PhD students at Leonard Wolfson Experimental Neuroscience Centre,Queen Square, London 2012-2017.
(1) NIHR Comprehensive Biomedical Research Centre, co- applicant, New Initiative ref 20, 1/1/2009-31/12/2012; (2) NIHR, Senior Investigator, 2008-2016
NONE
(1) Medical Research Council, grant ref MC_PC_12024, 2012- 2014; (2) The Wolfson Foundation, grant ref 18575, 2012- 2017; (3) Wellcome Trust, grant ref 097815/Z/11/Z, 2012- 2013;grant ref 099557/Z/12/A; (4) Multiple Sclerosis Society of GB, award 984,2013-2018; SRH Holding, project 2012-910001, 2012-2014
NONE
NONE
NONE
NONE
NONE
NONE
- From the Multiple Sclerosis International Federation (P.B., D.C., C.A.), London, UK; University of British Columbia (H.T.), Vancouver, Canada; Department of Non-Communicable Disease Epidemiology (C.B.), London School of Hygiene and Tropical Medicine, London, UK; Menzies Research Institute Tasmania (B.V.T.), University of Tasmania, Hobart, Australia; and Faculty of Brain Sciences (A.J.T.), University College London and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
- Correspondence to Dr. Thompson: alan.thompson{at}ucl.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.